R3 Bio Grows Headless Human Bodyoids for Drug Testing
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- R3 Bio is developing genetically engineered "bodyoids"—complete organ systems grown without brains—to replace laboratory animals in drug testing and preclinical research.
- Alice Gilman, CEO of R3 Bio, says the pharmaceutical industry needs systemic change because nine out of ten drugs that succeed in animal trials still fail in humans.
- R3 Bio uses induced pluripotent stem cells (iPSCs) to grow the brain‑free structures, with funding from billionaire Tim Draper and Singaporean investment fund Immortal Dragons.
- R3 Bio clarifies it has never claimed to create non‑sentient human clones, emphasizing that its current focus is on research platforms rather than hypothetical cloning.
- R3 Bio envisions the bodyoids eventually providing transplantable human tissues, but acknowledges significant regulatory and ethical questions about human‑derived biological platforms.
Why it matters: R3 Bio’s brain‑free bodyoids give drug developers a human‑relevant testing platform, addressing the high failure rate of animal‑based trials, while also opening a path to lab‑grown transplantable tissues. The approach triggers regulatory and ethical challenges that must be addressed before widespread global adoption.
Ask SkimNews
